Emerging experience with meningococcal serogroup B protein vaccines
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging experience with meningococcal serogroup B protein vaccines
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume 16, Issue 5, Pages 433-451
Publisher
Informa UK Limited
Online
2017-04-05
DOI
10.1080/14760584.2017.1308828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial
- (2017) Marco Aurelio P. Safadi et al. VACCINE
- Routinely vaccinating adolescents against meningococcus: targeting transmission & disease
- (2016) Volker Vetter et al. Expert Review of Vaccines
- Impact of Moderate Temperature Changes on Neisseria meningitidis Adhesion Phenotypes and Proteome
- (2016) Martin Lappann et al. INFECTION AND IMMUNITY
- Meningococcal B Vaccine during a University Outbreak
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of a Meningococcal B Vaccine during a University Outbreak
- (2016) Nicole E. Basta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age
- (2016) Matthew D. Snape et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents
- (2016) Derek Muse et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine
- (2016) Shelly Senders et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries
- (2016) Raquel Abad et al. PLoS One
- Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined
- (2016) Massimiliano Biagini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB
- (2016) Sonia Budroni et al. VACCINE
- A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults
- (2016) Lars Ostergaard et al. VACCINE
- Clinical experience with the meningococcal B vaccine, Bexsero ® : Prospects for reducing the burden of meningococcal serogroup B disease
- (2016) Philip S. Watson et al. VACCINE
- MenB vaccine programme cuts cases of meningitis and septicaemia in infants
- (2016) Jacqui Wise BMJ-British Medical Journal
- MenB vaccine programme cuts cases of meningitis and septicaemia in infants
- (2016) Jacqui Wise BMJ-British Medical Journal
- Notes from the Field:Outbreak of Serogroup B Meningococcal Disease at a University — California, 2016
- (2016) Hope H. Biswas et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents
- (2016) Timo Vesikari et al. Journal of the Pediatric Infectious Diseases Society
- Enter B and W: two new meningococcal vaccine programmes launched
- (2015) Shamez N Ladhani et al. ARCHIVES OF DISEASE IN CHILDHOOD
- Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets
- (2015) Dennis K.S. Law et al. BMC MICROBIOLOGY
- Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months
- (2015) Fiona McQuaid et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- A Large Portion of Meningococcal Antigen Typing System-Negative Meningococcal Strains from Spain Is Killed by Sera from Adolescents and Infants Immunized with 4CMenB
- (2015) R. Abad et al. Clinical and Vaccine Immunology
- Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015
- (2015) H Campbell et al. Eurosurveillance
- Neisseria meningitidisserogroup B bivalent factor H binding protein vaccine
- (2015) Nathan James Brendish et al. Expert Review of Vaccines
- Neisseria meningitidisfactor H-binding protein fHbp: a key virulence factor and vaccine antigen
- (2015) Kate L Seib et al. Expert Review of Vaccines
- The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme – New challenges for public health
- (2015) Shamez N. Ladhani et al. JOURNAL OF INFECTION
- Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine
- (2015) Dan M. Granoff et al. JOURNAL OF INFECTIOUS DISEASES
- First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak
- (2015) L. A. McNamara et al. PEDIATRICS
- Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000–2013: Vaccine program impact assessment
- (2015) A.E. Wormsbecker et al. VACCINE
- Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study
- (2015) Kirsten P. Perrett et al. VACCINE
- MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine
- (2015) Duccio Medini et al. VACCINE
- A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial
- (2015) Stan L. Block et al. VACCINE
- Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children
- (2015) Timo Vesikari et al. VACCINE
- Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?
- (2015) Jamie Findlow Human Vaccines & Immunotherapeutics
- Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013
- (2015) Michael Bröker et al. Human Vaccines & Immunotherapeutics
- Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes
- (2015) Alexander Domnich et al. Journal of Immunology Research
- Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015
- (2015) Jessica R. MacNeil et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents
- (2015) Timo Vesikari et al. Journal of the Pediatric Infectious Diseases Society
- Neisseria meningitidis porA, fetA and fHbp gene distribution in Western Australia 2000 to 2011
- (2014) Peter Boan et al. BMC INFECTIOUS DISEASES
- Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
- (2014) Georgina Tzanakaki et al. BMC MICROBIOLOGY
- Neisseria Adhesin A Variation and Revised Nomenclature Scheme
- (2014) Stefania Bambini et al. Clinical and Vaccine Immunology
- Increase in Endemic Neisseria meningitidis Capsular Group W Sequence Type 11 Complex Associated With Severe Invasive Disease in England and Wales
- (2014) Shamez N. Ladhani et al. CLINICAL INFECTIOUS DISEASES
- Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America
- (2014) R. ABAD et al. EPIDEMIOLOGY AND INFECTION
- Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
- (2014) Robert C Read et al. LANCET
- Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age
- (2014) Fiona McQuaid et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants
- (2014) Federico Martinon-Torres et al. VACCINE
- A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)
- (2014) Oliver Koeberling et al. VACCINE
- A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)
- (2014) Susanna Esposito et al. Human Vaccines & Immunotherapeutics
- A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)
- (2014) Roman Prymula et al. Human Vaccines & Immunotherapeutics
- The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease
- (2014) Gary W Zlotnick et al. Human Vaccines & Immunotherapeutics
- Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
- (2013) M. D. Snape et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
- (2013) Miguel O’Ryan et al. DRUGS
- Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
- (2013) Timo Vesikari et al. LANCET
- Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
- (2013) Ulrich Vogel et al. LANCET INFECTIOUS DISEASES
- Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease
- (2013) L. K. McNeil et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups
- (2013) Susan K. Hoiseth et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage
- (2013) Giacomo Frosi et al. VACCINE
- A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults
- (2013) Helen S. Marshall et al. VACCINE
- Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice
- (2013) Raffaella Rossi et al. VACCINE
- Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)
- (2013) Julie A. Bettinger et al. VACCINE
- Conservation of Meningococcal Antigens in the Genus Neisseria
- (2013) A. Muzzi et al. mBio
- Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
- (2013) Maria Elena Santolaya et al. Human Vaccines & Immunotherapeutics
- Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines
- (2012) Brian D. Plikaytis et al. Clinical and Vaccine Immunology
- Transcriptional Regulation of thenadAGene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine
- (2012) Luca Fagnocchi et al. INFECTION AND IMMUNITY
- Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules
- (2012) Nicoletta Gossger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
- (2012) María Elena Santolaya et al. LANCET
- Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial
- (2012) Peter C Richmond et al. LANCET INFECTIOUS DISEASES
- Molecular Epidemiology of Neisseria meningitidis Serogroup B in Brazil
- (2012) Ivano de Filippis et al. PLoS One
- The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens
- (2012) Davide Serruto et al. VACCINE
- Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease
- (2012) Patricia Kaaijk et al. VACCINE
- Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?
- (2012) Eva Hong et al. VACCINE
- The changing epidemiology of meningococcal disease in North America 1945–2010
- (2012) Carmen Baccarini et al. Human Vaccines & Immunotherapeutics
- Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules
- (2012) Steven Johnson et al. PLoS Pathogens
- Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion
- (2011) Paolo Montanari et al. CELLULAR MICROBIOLOGY
- Characterization of Neisseria meningitidis Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein
- (2011) Jay Lucidarme et al. Clinical and Vaccine Immunology
- Carriage ofNeisseria meningitidisin Europe: a review of studies undertaken in the region
- (2011) Montse Soriano-Gabarró et al. Expert Review of Anti-Infective Therapy
- The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans
- (2011) Daniela Toneatto et al. Human vaccines & immunotherapeutics
- Complement-Mediated Bactericidal Activity of Anti-Factor H Binding Protein Monoclonal Antibodies against the Meningococcus Relies upon Blocking Factor H Binding
- (2011) Serena Giuntini et al. INFECTION AND IMMUNITY
- Neisseria meningitidisAdhesin NadA Targets β1 Integrins
- (2011) Virginie Nägele et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structure of the C-terminal Domain ofNeisseriaHeparin Binding Antigen (NHBA), One of the Main Antigens of a Novel Vaccine againstNeisseria meningitidis
- (2011) Veronica Esposito et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak
- (2011) François Caron et al. LANCET INFECTIOUS DISEASES
- Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States
- (2011) Xin Wang et al. VACCINE
- Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen
- (2011) David M. Vu et al. VACCINE
- A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression
- (2011) P.B. Keiser et al. VACCINE
- Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates
- (2010) Alan Kimura et al. Clinical and Vaccine Immunology
- Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy
- (2010) Jamie Findlow et al. CLINICAL INFECTIOUS DISEASES
- The epidemiology of meningococcal disease and the impact of vaccines
- (2010) Ameneh Khatami et al. Expert Review of Vaccines
- Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies
- (2010) Kate L. Seib et al. INFECTION AND IMMUNITY
- Meningococcal carriage by age: a systematic review and meta-analysis
- (2010) Hannah Christensen et al. LANCET INFECTIOUS DISEASES
- Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age
- (2010) Matthew D. Snape et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans
- (2010) Davide Serruto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines
- (2010) J. Donnelly et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage
- (2010) Dlawer A.A. Ala’Aldeen et al. VACCINE
- Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus
- (2010) Marzia M. Giuliani et al. VACCINE
- Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
- (2010) Han-Qing Jiang et al. VACCINE
- Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa
- (2010) Kedibone M. Mothibeli et al. VACCINE
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease
- (2009) Amanda C. Cohn et al. CLINICAL INFECTIOUS DISEASES
- Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis
- (2009) Ellen Murphy et al. JOURNAL OF INFECTIOUS DISEASES
- Variation of the factor H-binding protein of Neisseria meningitidis
- (2009) C. Brehony et al. MICROBIOLOGY-SGM
- Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates
- (2009) Muriel C. Schneider et al. NATURE
- Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis
- (2009) Johan Holst et al. VACCINE
- Global epidemiology of meningococcal disease
- (2009) Lee H. Harrison et al. VACCINE
- Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates
- (2009) Rolando Pajon et al. VACCINE
- Complement‐Dependent Synergistic Bactericidal Activity of Antibodies against Factor H–Binding Protein, a Sparsely Distributed Meningococcal Vaccine Antigen
- (2008) Jo Anne Welsch et al. JOURNAL OF INFECTIOUS DISEASES
- Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA)
- (2008) Susanna Franzoso et al. JOURNAL OF LEUKOCYTE BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started